

Anca L Grosu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8260820/publications.pdf>

Version: 2024-02-01

143
papers

4,531
citations

109321

35
h-index

128289

60
g-index

147
all docs

147
docs citations

147
times ranked

5792
citing authors

#	ARTICLE	IF	CITATIONS
1	ESTRO-ACROP guideline –target delineation of glioblastomas–. Radiotherapy and Oncology, 2016, 118, 35-42.	0.6	286
2	An Interindividual Comparison of O-(2- [18F]Fluoroethyl)-L-Tyrosine (FET) – and L-[Methyl-11C]Methionine (MET) –PET in Patients With Brain Gliomas and Metastases. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1049-1058.	0.8	222
3	How to use functional imaging information for radiotherapy planning. European Journal of Cancer, 2009, 45, 461-463.	2.8	160
4	PET imaging in patients with meningioma –report of the RANO/PET Group. Neuro-Oncology, 2017, 19, 1576-1587.	1.2	157
5	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2014, 113, 317-323.	0.6	141
6	Comparison of ⁶⁸ Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics, 2017, 7, 228-237.	10.0	135
7	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2016, 121, 364-373.	0.6	130
8	Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men. Theranostics, 2014, 4, 412-419.	10.0	127
9	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(+) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research, 2016, 22, 2639-2649.	7.0	127
10	Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer. JAMA Oncology, 2022, 8, e215445.	7.1	127
11	Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 581-592.	10.7	121
12	SBRT in pancreatic cancer: What is the therapeutic window?. Radiotherapy and Oncology, 2015, 114, 109-116.	0.6	85
13	[68Ga]-PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard – Implications for focal radiotherapy planning in primary prostate cancer. Radiotherapy and Oncology, 2019, 141, 214-219.	0.6	83
14	Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. Radiotherapy and Oncology, 2015, 117, 113-117.	0.6	78
15	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro-Oncology, 2021, 23, 881-893.	1.2	75
16	Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer – A systematic review. Radiotherapy and Oncology, 2015, 114, 117-121.	0.6	73
17	Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies. Theranostics, 2016, 6, 862-874.	10.0	71
18	MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 889-897.	6.4	68

#	ARTICLE	IF	CITATIONS
19	Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1). <i>BMC Cancer</i> , 2016, 16, 769.	2.6	62
20	Outcome After PSMA PET/CT-Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 227-233.	5.0	61
21	A deep conical agarose microwell array for adhesion independent three-dimensional cell culture and dynamic volume measurement. <i>Lab on A Chip</i> , 2018, 18, 179-189.	6.0	55
22	Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. <i>Radiation Oncology</i> , 2018, 13, 81.	2.7	53
23	Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1463-1472.	6.4	51
24	Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 13-18.	4.4	51
25	Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?. <i>Radiation Oncology</i> , 2020, 15, 31.	2.7	51
26	Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68 Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. <i>Radiotherapy and Oncology</i> , 2017, 123, 472-477.	0.6	50
27	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2018, 142, 1911-1925.	5.1	50
28	First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments. <i>Radiation Oncology</i> , 2020, 15, 74.	2.7	50
29	Re-irradiation for Recurrent Primary Brain Tumors. <i>Anticancer Research</i> , 2016, 36, 4985-4996.	1.1	47
30	Stereotactic fractionated radiotherapy for Klatskin tumours. <i>Radiotherapy and Oncology</i> , 2010, 95, 99-102.	0.6	44
31	Simultaneous integrated protection. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 886-894.	2.0	43
32	Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) – a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG). <i>BMC Cancer</i> , 2020, 20, 532.	2.6	43
33	Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. <i>Radiotherapy and Oncology</i> , 2019, 141, 208-213.	0.6	42
34	ESTRO ACROP guideline for target volume delineation of skull base tumors. <i>Radiotherapy and Oncology</i> , 2021, 156, 80-94.	0.6	41
35	Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 579-586.	0.8	40
36	Impact of 4D-18FDG-PET/CT imaging on target volume delineation in SBRT patients with central versus peripheral lung tumors. Multi-reader comparative study. <i>Radiotherapy and Oncology</i> , 2015, 115, 335-341.	0.6	37

#	ARTICLE	IF	CITATIONS
37	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. <i>Radiotherapy and Oncology</i> , 2018, 127, 121-127.	0.6	37
38	Uncovering the invisible—prevalence, characteristics, and radiomics feature—based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1987-1997.	6.4	37
39	Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA). <i>Radiation Oncology</i> , 2017, 12, 107.	2.7	35
40	Prostate-specific Membrane Antigen Positron Emission Tomography—detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. <i>European Urology Focus</i> , 2021, 7, 309-316.	3.1	34
41	Expert consensus on re-irradiation for recurrent glioma. <i>Radiation Oncology</i> , 2017, 12, 194.	2.7	32
42	Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy—results from a prospective trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1046-1055.	6.4	32
43	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. <i>Liver Cancer</i> , 2019, 8, 281-294.	7.7	31
44	Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. <i>Radiographics</i> , 2021, 41, 1387-1407.	3.3	30
45	¹¹ C-Choline PET/pathology image coregistration in primary localized prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2242-2248.	6.4	29
46	Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy. <i>Acta Oncologica</i> , 2016, 55, 1299-1304.	1.8	28
47	The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2020, 150, 128-135.	0.6	28
48	Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases. <i>Cancer Medicine</i> , 2018, 7, 2319-2327.	2.8	27
49	Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis. <i>BMC Cancer</i> , 2018, 18, 807.	2.6	27
50	Intraindividual comparison between 68Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2796-2803.	6.4	27
51	A Novel miRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy. <i>PLoS ONE</i> , 2015, 10, e0118745.	2.5	27
52	Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET. <i>Radiation Oncology</i> , 2018, 13, 159.	2.7	26
53	The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. <i>Radiation Oncology</i> , 2018, 13, 65.	2.7	26
54	Improved inter-observer agreement of an expert review panel in an oncology treatment trial — Insights from a structured interventional process. <i>European Journal of Cancer</i> , 2015, 51, 2525-2533.	2.8	24

#	ARTICLE	IF	CITATIONS
55	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 125-131.	0.6	24
56	Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. <i>Radiation Oncology</i> , 2019, 14, 33.	2.7	24
57	Diffusion-weighted MRI and ADC versus FET-PET and Gd1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. <i>Radiotherapy and Oncology</i> , 2019, 130, 121-131.	0.6	24
58	Comparison of Manual and Semi-Automatic [18F]PSMA-1007 PET Based Contouring Techniques for Intraprostatic Tumor Delineation in Patients With Primary Prostate Cancer and Validation With Histopathology as Standard of Reference. <i>Frontiers in Oncology</i> , 2020, 10, 600690.	2.8	23
59	Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer. <i>EJNMMI Research</i> , 2020, 10, 62.	2.5	23
60	Estimation of the $\hat{\mu}/\hat{\sigma}^2$ ratio of non-small cell lung cancer treated with stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 142, 210-216.	0.6	22
61	Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases. <i>Clinical Neurology and Neurosurgery</i> , 2016, 142, 81-86.	1.4	21
62	Digital Follow-Up and the Perspective of Patient-Centered Care in Oncology: What's the PROblem?. <i>Oncology</i> , 2020, 98, 379-385.	1.9	21
63	The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer. <i>Radiation Oncology</i> , 2020, 15, 81.	2.7	21
64	The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 403-413.	2.0	20
65	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. <i>BMC Cancer</i> , 2020, 20, 362.	2.6	20
66	Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. <i>Radiotherapy and Oncology</i> , 2020, 148, 82-88.	0.6	20
67	The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancer. <i>Scientific Reports</i> , 2021, 11, 5836.	3.3	20
68	Explainable AI for CNN-based prostate tumor segmentation in multi-parametric MRI correlated to whole mount histopathology. <i>Radiation Oncology</i> , 2022, 17, 65.	2.7	20
69	Local control and overall survival after frameless radiosurgery: A single center experience. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 55-61.	1.7	19
70	Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1823-1832.	4.2	19
71	Development and validation of a novel prognostic score for elderly head-and-neck cancer patients undergoing radiotherapy or chemoradiation. <i>Radiotherapy and Oncology</i> , 2021, 154, 276-282.	0.6	19
72	PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial. <i>Cancers</i> , 2021, 13, 5795.	3.7	19

#	ARTICLE	IF	CITATIONS
73	Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy. <i>Stem Cell Research</i> , 2019, 40, 101536.	0.7	18
74	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.6	17
75	Repeated SBRT for in- and out-of-field recurrences in the liver. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 246-253.	2.0	17
76	Prospective randomized clinical studies involving reirradiation. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 679-686.	2.0	16
77	Preserving the legacy of reirradiation: A narrative review of historical publications. <i>Advances in Radiation Oncology</i> , 2017, 2, 176-182.	1.2	16
78	Second re-irradiation: a narrative review of the available clinical data. <i>Acta OncolÃ³gica</i> , 2018, 57, 305-310.	1.8	16
79	Predicted survival in patients with brain metastases from colorectal cancer: Is a current nomogram helpful?. <i>Clinical Neurology and Neurosurgery</i> , 2016, 143, 107-110.	1.4	15
80	Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection. <i>Cancer Medicine</i> , 2018, 7, 2350-2359.	2.8	15
81	Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial). <i>Journal of Thoracic Oncology</i> , 2019, 14, 408-419.	1.1	15
82	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2328-2338.	6.4	13
83	Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference. <i>Frontiers in Oncology</i> , 2021, 11, 652678.	2.8	12
84	App-Controlled Treatment Monitoring and Support for Head and Neck Cancer Patients (APCOT): Protocol for a Prospective Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e21693.	1.0	12
85	Financial toxicity in cancer patients treated with radiotherapy in Germanyâ€”a cross-sectional study. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 1053-1061.	2.0	12
86	PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 1025-1035.	0.8	12
87	The challenge of durable brain control in patients with brain-only metastases from breast cancer. <i>SpringerPlus</i> , 2015, 4, 585.	1.2	11
88	Short Survival Time after Palliative whole Brain Radiotherapy: Can We Predict Potential Overtreatment by Use of a Nomogram?. <i>Journal of Cancer</i> , 2017, 8, 1525-1529.	2.5	11
89	Unresectable hepatic PEComa: a rare malignancy treated with stereotactic body radiation therapy (SBRT) followed by complete resection. <i>Radiation Oncology</i> , 2018, 13, 28.	2.7	11
90	FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 27-38.	2.0	11

#	ARTICLE	IF	CITATIONS
91	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 640467.	2.8	11
92	Validation of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). <i>Journal of Clinical Medicine Research</i> , 2018, 10, 178-181.	1.2	11
93	Automatic Tumor Segmentation With a Convolutional Neural Network in Multiparametric MRI: Influence of Distortion Correction. <i>Tomography</i> , 2019, 5, 292-299.	1.8	11
94	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 801-810.	2.8	10
95	Surviving Elderly Patients with Head-and-Neck Squamous Cell Carcinoma—What Is the Long-Term Quality of Life after Curative Radiotherapy?. <i>Cancers</i> , 2021, 13, 1275.	3.7	10
96	Gastrin-Releasing Peptide Receptor Antagonist [68Ga]RM2 PET/CT for Staging of Pre-Treated, Metastasized Breast Cancer. <i>Cancers</i> , 2021, 13, 6106.	3.7	10
97	Long-term survival results after treatment for oligometastatic brain disease. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 307-311.	0.6	9
98	Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 8, 8-16.	2.9	8
99	Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects. <i>Future Oncology</i> , 2018, 14, 751-769.	2.4	7
100	Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis. <i>Cancers</i> , 2020, 12, 3395.	3.7	7
101	Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition. <i>Radiation Oncology</i> , 2020, 15, 242.	2.7	7
102	Impact of a low FODMAP diet on the amount of rectal gas and rectal volume during radiotherapy in patients with prostate cancer—a prospective pilot study. <i>Radiation Oncology</i> , 2020, 15, 27.	2.7	7
103	Radiotherapeutic management of cervical lymph node metastases from an unknown primary site—experiences from a large cohort treated with modern radiation techniques. <i>Radiation Oncology</i> , 2020, 15, 80.	2.7	7
104	Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy—Results from a large multicenter analysis. <i>Radiotherapy and Oncology</i> , 2021, 156, 266-274.	0.6	7
105	Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?. <i>Radiotherapy and Oncology</i> , 2021, 159, 17-20.	0.6	7
106	Development of a Score Predicting Survival after Palliative Reirradiation. <i>Journal of Oncology</i> , 2014, 2014, 1-7.	1.3	6
107	Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA). <i>Radiation Oncology</i> , 2020, 15, 35.	2.7	6
108	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. <i>Pharmacogenomics Journal</i> , 2021, 21, 37-46.	2.0	6

#	ARTICLE	IF	CITATIONS
109	Evolution of the hypoxic compartment on sequential oxygen partial pressure maps during radiochemotherapy in advanced head and neck cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 17, 100-105.	2.9	6
110	Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial. <i>Radiotherapy and Oncology</i> , 2021, 163, 32-38.	0.6	6
111	Isotropic Expansion of the Intraprostatic Gross Tumor Volume of Primary Prostate Cancer Patients Defined in MRI—A Correlation Study With Whole Mount Histopathological Information as Reference. <i>Frontiers in Oncology</i> , 2020, 10, 596756.	2.8	5
112	Hyperthermia Plus Re-Irradiation in the Management of Unresectable Locoregional Recurrence of Breast Cancer in Previously Irradiated Sites. <i>Journal of Clinical Oncology</i> , 2020, 38, 3576-3577.	1.6	5
113	A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa. <i>Frontiers in Oncology</i> , 2021, 11, 723536.	2.8	5
114	Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies. <i>Cancers</i> , 2021, 13, 5725.	3.7	5
115	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.6	5
116	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC – Hypothesis generation on a multicentre cohort of the DKTK-ROG. <i>Radiotherapy and Oncology</i> , 2022, 169, 8-14.	0.6	5
117	Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 62-67.	0.6	4
118	Retroperitoneal soft tissue sarcoma: low-dose neoadjuvant radiation therapy followed by surgery with or without intraoperative radiotherapy and adjuvant radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 558-565.	2.0	4
119	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.6	4
120	Normal tissue studies in radiation oncology: A systematic review of highly cited articles and citation patterns. <i>Oncology Letters</i> , 2014, 8, 972-976.	1.8	3
121	Imaging for radiation treatment planning and monitoring in prostate Cancer: Precision, personalization, individualization of therapy. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 11, 61-62.	2.9	3
122	Does overall treatment time impact on survival after whole-brain radiotherapy for brain metastases?. <i>Clinical and Translational Oncology</i> , 2011, 13, 885-888.	2.4	2
123	Biological imaging for individualized therapy in radiation oncology: part I physical and technical aspects. <i>Future Oncology</i> , 2018, 14, 737-749.	2.4	2
124	ACTR-49. PriCoTTF: A PHASE I/II TRIAL OF TUMOR TREATING FIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi22-vi23.	1.2	2
125	Value of PET imaging for radiation therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 326-343.	0.7	2
126	Human mesenchymal stromal cells maintain their stem cell traits after high-LET particle irradiation – Potential implications for particle radiotherapy and manned space missions. <i>Cancer Letters</i> , 2022, 524, 172-181.	7.2	2

#	ARTICLE	IF	CITATIONS
127	Human Mesenchymal Stromal Cells Do Not Cause Radioprotection of Head-and-Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7689.	4.1	2
128	Hypoxia and positron emission tomography in patients with gliomas. <i>Clinical and Translational Imaging</i> , 2017, 5, 447-453.	2.1	1
129	The Role of Particle Therapy for the Treatment of Skull Base Tumors and Tumors of the Central Nervous System (CNS). <i>Topics in Magnetic Resonance Imaging</i> , 2019, 28, 49-61.	1.2	1
130	A 6-gene signature for outcome prediction of grade II/III glioma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2002-2002.	1.6	1
131	Molecular Imaging in Photon Radiotherapy. <i>Recent Results in Cancer Research</i> , 2020, 216, 845-863.	1.8	1
132	Improvement of diffusion weighted MRI by practical B0 homogenization for head & neck cancer patients undergoing radiation therapy. <i>Physica Medica</i> , 2022, 97, 59-65.	0.7	1
133	Abstract 3156: Tumor Treating Fields reduce cellular survival of human mesenchymal stromal cells via apoptosis and senescence induction. <i>Cancer Research</i> , 2022, 82, 3156-3156.	0.9	1
134	Scientific impact of studies published in temporarily available radiation oncology journals: a citation analysis. <i>SpringerPlus</i> , 2015, 4, 93.	1.2	0
135	GENE-27. GENOME-WIDE DNA METHYLATION PROFILING IN GRADE II AND III GLIOMAS REVEALS A SUBSET OF GENES WITH PROGNOSTIC SIGNIFICANCE CONTROLLED BY PROMOTER METHYLATION. <i>Neuro-Oncology</i> , 2018, 20, vi109-vi109.	1.2	0
136	CSIG-21. THE ROLE OF miR-219a-2-3p AS A TUMOR SUPPRESSOR IN IDH1/2-WILD-TYPE GRADE II/III GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi47-vi47.	1.2	0
137	Radiate Once More. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 314-315.	0.8	0
138	Measuring breathing induced oesophageal motion and its dosimetric impact. <i>Physica Medica</i> , 2021, 88, 9-19.	0.7	0
139	Randomized Controlled Clinical Trials in Radiation Therapy: Patterns of Publication in the Most Frequently Cited Studies. <i>Medical Science Review</i> , 0, 2, 104-110.	0.0	0
140	Mathematical Description of Changes in Tumour Oxygenation from Repeated Functional Imaging. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1072, 195-200.	1.6	0
141	CTNI-79. PRICOTTF TRIAL: A PHASE I/II TRIAL OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii61-ii61.	1.2	0
142	Implementation of PSMA-PET in focal dose-escalated radiotherapy of primary prostate cancer patients: Results of a planned safety analysis of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 260-260.	1.6	0
143	Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. <i>Results of the Phase II NIVES Study. European Urology</i> , 2022, , .	1.9	0